Erratum: Corrigendum: Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition

Vaccari, Monica; Gordon, Shari N.; Fourati, Slim; Schifanella, Luca; Liyanage, Namal P. M.; Cameron, Mark J.; Keele, Brandon F.; Shen, Xiaoying; Tomaras, Georgia D.; Billings, Erik; Rao, Mana; Chung, Amy W.; Dowell, Karen G.; Bailey‐Kellogg, Chris; Brown, Eric N.; Ackerman, Margaret E.; Vargas-Inchaustegui, Diego A.; Whitney, Stephen; Doster, Melvin N.; Binello, Nicolò; Pegu, Poonam; Montefiori, David C.; Foulds, Kathryn E.; Quinn, David S.; Donaldson, Mitzi M.; Liang, Frank; Loré, Karin; Koup, Richard A.; McDermott, Adrian B.; Ma, Zhien; Miller, Christopher J.; Phan, Tran B.; Forthal, Donald N.; Blackburn, Matthew; Caccuri, Francesca; Bissa, Massimiliano; Ferrari, Guido; Kalyanaraman, Vaniambadi S.; Ferrari, Maria Grazia; Thompson, DeVon; Robert-Guroff, Marjorie; Ratto‐Kim, Silvia; Kim, Jerome H.; Michael, Nelson L.; Phogat, Sanjay; Barnett, Susan W.; Tartaglia, Jim; Venzon, David; Stablein, Donald M.; Alter, Galit; Sékaly, Rafick‐Pierre; Franchini, Genoveffa

doi:10.1038/nm1016-1192a

Cited by 13 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At 10 and 60 days post-boost, blood was harvested by submandibular bleeding to determine adaptive and memory humoral HIV-1 gp140-specific immune responses, respectively. One week post-second bleed, animals from all groups (1)(2)(3)(4)(5)(6)(7)(8) were boosted with 10 µg of gp140(97CN54) protein + 5 µg of MPLA as adjuvant by i.m. route and 10 days post-protein boost, mice were sacrificed and spleens and draining lymph nodes (DLNs) processed for ICS assay and sera harvested for ELISA to determine both cellular and humoral responses against HIV-1 gp140 protein, respectively.…”

Section: Mouse Immunizationmentioning

confidence: 99%

“…To date, only one HIV-1 phase III clinical trial (Thai RV144 trial) has reported some efficacy (31.2%) against HIV-1 acquisition (5). At present, the evaluation of the vaccineinduced immune correlates of protection in non-human primates (NHPs) and in humans, such as broadly neutralizing antibodies (bNAbs), non-neutralizing antibodies targeting the variable loops 1 and 2 (V1/V2) of the HIV-1 envelope (Env), Env-specific polyfunctional antibodies and T cell responses, are guiding different HIV-1 vaccine approaches and regimens (6)(7)(8). The RV144 regimen, novel vaccines based on adenovirus vectors, mosaic immunogens, optimized gp140 proteins (such as HIV-1 Env SOSIP trimers) and passive administration of monoclonal antibodies are among the most recent strategies for HIV-1 prevention and treatment.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses

et al. 2019

View full text Add to dashboard Cite

Perdiguero et al. VSV-GP/NYVAC Combination Against HIV-1 subclasses, while the other groups showed a Th2-associated IgG1 bias. In summary, our T and B cell population data demonstrated that VSV-GP-based vectors could be taken into consideration as an optimized immunogenic HIV-1 vaccine candidate component against HIV-1 when used for priming in heterologous combinations with the poxvirus vector NYVAC as a boost.

show abstract

Section: Mouse Immunizationmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The modest efficacy of the RV144 HIV-1 vaccine candidate and the analyses of vaccine-induced immune correlates of protection in humans and NHP models [ 8 , 9 , 10 ] are currently guiding the development of novel HIV-1 vaccines [ 71 ]. Preventative and therapeutic strategies have been pursued and investigated into test-of-concept clinical trials with the aim to provide protection against HIV-1 [ 72 , 73 ].…”

Section: Current Hiv-1 Vaccine Approachesmentioning

confidence: 99%

“…So far, only one HIV-1 vaccine clinical trial—the Thai Phase III RV144—demonstrated some efficacy of vaccination against HIV-1 acquisition [ 7 ]. Currently, the analyses of vaccine-induced immune correlates of protection in humans and non-human primate (NHP) models are guiding different HIV-1 vaccine approaches [ 8 , 9 , 10 ]. In this review, we provide a general overview of the recent advances in HIV-1 vaccine development, with a focus on the immunological mechanisms.…”

Section: Introductionmentioning

confidence: 99%

HIV Vaccination: A Roadmap among Advancements and Concerns

Trovato

D’Apice

Prisco

et al. 2018

IJMS

View full text Add to dashboard Cite

Since the identification of the Human Immunodeficiency Virus type 1 (HIV-1) as the etiologic agent of AIDS (Acquired Immunodeficiency Syndrome), many efforts have been made to stop the AIDS pandemic. A major success of medical research has been the development of the highly active antiretroviral therapy and its availability to an increasing number of people worldwide, with a considerable effect on survival. However, a safe and effective vaccine able to prevent and eradicate the HIV pandemic is still lacking. Clinical trials and preclinical proof-of-concept studies in nonhuman primate (NHP) models have provided insights into potential correlates of protection against the HIV-1 infection, which include broadly neutralizing antibodies (bnAbs), non-neutralizing antibodies targeting the variable loops 1 and 2 (V1V2) regions of the HIV-1 envelope (Env), polyfunctional antibody, and Env-specific T-cell responses. In this review, we provide a brief overview of different HIV-1 vaccine approaches and discuss the current understanding of the cellular and humoral correlates of HIV-1 immunity.

show abstract

“…Unfortunately, to date, HIV-1 vaccine candidates have largely been unsuccessful in human clinical trials. Despite promising preclinical results in nonhuman primate (NHP) studies (1)(2)(3)(4)(5)(6), the majority of candidate vaccines have failed to elicit similarly potent immunogenicity or protection when subsequently tested in humans (7)(8)(9)(10). The development of a small-animal model capable of supporting HIV-1 infection and recapitulating HIV-1-specific human immunity may help accelerate the design and testing of next-generation HIV-1 vaccines.…”

mentioning

confidence: 99%

Immunization of BLT Humanized Mice Redirects T Cell Responses to Gag and Reduces Acute HIV-1 Viremia

Claiborne

Dudek

Maldini

et al. 2019

J Virol

View full text Add to dashboard Cite

BLT (bone marrow-liver-thymus) humanized mice, which reconstitute a functional human immune system, develop prototypic human virus-specific CD8+ T cell responses following infection with human immunodeficiency virus type 1 (HIV-1). We explored the utility of the BLT model for HIV-1 vaccine development by immunizing BLT mice against the conserved viral Gag protein, utilizing a rapid prime-boost protocol of poly(lactic-co-glycolic) acid microparticles and a replication-defective herpes simplex virus (HSV) recombinant vector. After HIV-1 challenge, the mice developed broad, proteome-wide gamma interferon-positive (IFN-γ+) T cell responses against HIV-1 that reached magnitudes equivalent to what is observed in HIV-1-infected individuals. The functionality of these responses was underscored by the consistent emergence of escape mutations in multiple CD8+ T cell epitopes during the course of infection. Although prechallenge vaccine-induced responses were largely undetectable, the Gag immunization increased both the magnitude and the kinetics of anamnestic Gag-specific T cell responses following HIV-1 infection, and the magnitude of these postchallenge Gag-specific responses was inversely correlated with acute HIV-1 viremia. Indeed, Gag immunization was associated with a modest but significant 0.5-log reduction in HIV-1 viral load when analyzed across four experimental groups of BLT mice. Notably, the HSV vector induced elevated plasma concentrations of polarizing cytokines and chemotactic factors, including interleukin-12p70 (IL-12p70) and MIP-1α, which were positively correlated with the magnitude of Gag-specific responses. Overall, these results support the ability of BLT mice to recapitulate human pathogen-specific T cell responses and to respond to immunization; however, additional improvements to the model are required to develop a robust system for testing HIV-1 vaccine efficacy. IMPORTANCE Advances in the development of humanized mice have raised the possibility of a small-animal model for preclinical testing of an HIV-1 vaccine. Here, we describe the capacity of BLT humanized mice to mount broadly directed HIV-1-specific human T cell responses that are functionally active, as indicated by the rapid emergence of viral escape mutations. Although immunization of BLT mice with the conserved viral Gag protein did not result in detectable prechallenge responses, it did increase the magnitude and kinetics of postchallenge Gag-specific T cell responses, which was associated with a modest but significant reduction in acute HIV-1 viremia. Additionally, the BLT model revealed immunization-associated increases in the plasma concentrations of immunomodulatory cytokines and chemokines that correlated with more robust T cell responses. These data support the potential utility of the BLT humanized mouse for HIV-1 vaccine development but suggest that additional improvements to the model are warranted.

show abstract

Erratum: Corrigendum: Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition

Cited by 13 publications

References 0 publications

Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses

Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses

HIV Vaccination: A Roadmap among Advancements and Concerns

Immunization of BLT Humanized Mice Redirects T Cell Responses to Gag and Reduces Acute HIV-1 Viremia

Contact Info

Product

Resources

About